A clinical case of atopic dermatitis with a rapid positive effect from the use of a genetically engineered biological drug in a teenager
Introduction. The instructions for the drug dupilumab indicate that the administration of a single loading dose on the first day leads to the rapid achievement of clinically effective concentrations within 2 weeks, which we saw in the example of our patient and her real clinical response to the firs...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Association of Paediatric Allergists and Immunologists of Russia (APAIR)
2024-05-01
|
| Series: | Аллергология и Иммунология в Педиатрии |
| Subjects: | |
| Online Access: | https://adair.elpub.ru/jour/article/view/128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. The instructions for the drug dupilumab indicate that the administration of a single loading dose on the first day leads to the rapid achievement of clinically effective concentrations within 2 weeks, which we saw in the example of our patient and her real clinical response to the first injection. Presentation of a clinical case. Under our medical supervision was a 17-year-old patient with severe atopic dermatitis, resistant to traditional therapy. Heredity for allergic pathology is burdened: the girl’s mother suffers from pollen allergy. Initially before the start of therapy: SCORAD — 88 points, EASI — 48.8 points, IGA — 4, blood eosinophils — 11 % (1188 cells/ml), total IgE — 1102.0 IU/ml; the content of nitric oxide in exhaled air (FeNO) is 30 ppb. On April 28, 2021, the patient was administered dupilumab at a dose of 600 mg. Assessment of atopic dermatitis control in points upon admission to the hospital 2 weeks after the first administration of dupilumab: on the SCORAD scale — 44.5 points; EASI — 13.8 points; IGA — 2 points, eosinophils — 9 % (1070 cells/ml); total IgE — 840 IU/ml; FeNO — 5 ppb. Conclusion. This clinical observation clearly illustrates the fact that patients with severe atopic dermatitis who don’t respond to first-line therapy can achieve positive clinical results after the first use of a recombinant human monoclonal antibody (IgG4). |
|---|---|
| ISSN: | 2500-1175 2712-7958 |